PPV UNiSZ Experience.pptx
•Download as PPTX, PDF•
0 likes•4 views
1. The document summarizes the experience of the UniSZA Vaccination Centre in running Malaysia's national COVID-19 vaccination program. 2. It provides an overview of the vaccination process and details the administration, quality assurance, vaccinator training, and challenges faced at the centre such as client data management and ensuring proper vaccine storage. 3. The centre administered over 30,000 vaccine doses with fewer than 1% resulting in adverse effects, most of which were manageable at the facility. Support from stakeholders was identified as critical to the success of the vaccination effort.
Report
Share
Report
Share
Recommended
COVID-19 Vaccine Trials: Why we still need them?
Webinar Series on Demystifying Phases in Clinical Trials & COVID-19 Updates organized by Institute for Clinical Research (ICR), NIH
Speaker: Dr. Cheah Wee Kooi, Physician & Geriatrician, Head of Medical Dept & Clinical Research Centre, Taiping Hospital
More information please visit: https://clinupcovid.mailerpage.com/resources/r0x8r9-webinar-series-on-demystifying-cl
Introduction and Malaysia’s Experience in Phase 1 Clinical Trials
Introduction and Malaysia’s Experience in Phase 1 Clinical TrialsInstitute for Clinical Research (ICR)
Webinar Series on Demystifying Phases in Clinical Trials & COVID-19 Updates organized by Institute for Clinical Research (ICR), NIH
Speaker: Dr. Alan Fong Yean Yip, Consultant Cardiologist & CRC head of Sarawak General Hospital and Mr. Chew Chun Keat, Technical Head of Centre for Clinical Trial, ICR
More information please visit: https://clinupcovid.mailerpage.com/resources/r0x8r9-webinar-series-on-demystifying-clFellowship in Infectious Diseases
Enroll today in Fellowship in Infectious Diseases with Medvarsity online limited and upskill with case discussions.
SGS Expertise for COVID-19 Clinical Trials
We offer a wide range of services for COVID-19 clinical trials, including regulatory support, CPU Phase I unit, patient recruitment, end-to-end trial management, biometrics and infectious disease expertise. Find out more: https://www.sgs.com/en/campaigns/sgs-life-sciences-during-covid-19
Lessons learnt from phase 1 roll-out of COVID-19 vaccines
Webinar Series on COVID-19 vaccine: Jointly organized by Malaysian Society of Infection Control and Infectious Diseases (MyICID) & Institute for Clinical Research (ICR), NIH
Speaker: Dr. Norzaihan binti Hassan, Family Medicine Consultant working in Klinik Kesihatan Bandar Kota Bharu, Ministry of Health Malaysia.
4th Issue of CRC Perak Network Bulletin (2021)
This bulletin is a publication of the CRC networks in Perak (Hospital Raja Permaisuri Bainun Ipoh, Hospital Seri Manjung and Hospital Taiping).
This issue emcompasses various research articles written by CRC staff, a research scope write-up to emphasize on the research focus this coming year, programmes conducted in 2021 as well as upcoming events across the CRC Perak Network this year.
(e-ISSN Number: 2682-7867).
Preparedness for Covid 19 3rd wave ,.pptx
The document discusses preparedness for India's potential third wave of Covid-19, focusing on vaccination awareness and recommended precautions. It summarizes the history and characteristics of the first two waves, predicts younger children and adolescents may be more affected in the third wave. The document emphasizes the importance of vaccination, physical activity, nutrition, hygiene and continued safety measures like masks and distancing to reduce risks of severe illness.
2023JUL_Webinar_Ped QoC (1) (1).pptx by mitiku
The document summarizes a webinar on advancing pediatric quality of care held by the Child Health Task Force. It includes:
- Agenda items on sharing country efforts to improve pediatric quality from Kenya and Uganda, outcomes of recent discussions, and a roundtable discussion.
- Kenya has made progress developing pediatric quality standards and indicators, piloting a health facility assessment tool, and mapping indicators to their health information system. Challenges include resources for wide implementation and institutionalizing standards.
- Uganda has seen steady reductions in childhood mortality since 1989 through programs addressing leading causes of death. Future focus is strengthening health systems to support quality service delivery across all levels of care.
Recommended
COVID-19 Vaccine Trials: Why we still need them?
Webinar Series on Demystifying Phases in Clinical Trials & COVID-19 Updates organized by Institute for Clinical Research (ICR), NIH
Speaker: Dr. Cheah Wee Kooi, Physician & Geriatrician, Head of Medical Dept & Clinical Research Centre, Taiping Hospital
More information please visit: https://clinupcovid.mailerpage.com/resources/r0x8r9-webinar-series-on-demystifying-cl
Introduction and Malaysia’s Experience in Phase 1 Clinical Trials
Introduction and Malaysia’s Experience in Phase 1 Clinical TrialsInstitute for Clinical Research (ICR)
Webinar Series on Demystifying Phases in Clinical Trials & COVID-19 Updates organized by Institute for Clinical Research (ICR), NIH
Speaker: Dr. Alan Fong Yean Yip, Consultant Cardiologist & CRC head of Sarawak General Hospital and Mr. Chew Chun Keat, Technical Head of Centre for Clinical Trial, ICR
More information please visit: https://clinupcovid.mailerpage.com/resources/r0x8r9-webinar-series-on-demystifying-clFellowship in Infectious Diseases
Enroll today in Fellowship in Infectious Diseases with Medvarsity online limited and upskill with case discussions.
SGS Expertise for COVID-19 Clinical Trials
We offer a wide range of services for COVID-19 clinical trials, including regulatory support, CPU Phase I unit, patient recruitment, end-to-end trial management, biometrics and infectious disease expertise. Find out more: https://www.sgs.com/en/campaigns/sgs-life-sciences-during-covid-19
Lessons learnt from phase 1 roll-out of COVID-19 vaccines
Webinar Series on COVID-19 vaccine: Jointly organized by Malaysian Society of Infection Control and Infectious Diseases (MyICID) & Institute for Clinical Research (ICR), NIH
Speaker: Dr. Norzaihan binti Hassan, Family Medicine Consultant working in Klinik Kesihatan Bandar Kota Bharu, Ministry of Health Malaysia.
4th Issue of CRC Perak Network Bulletin (2021)
This bulletin is a publication of the CRC networks in Perak (Hospital Raja Permaisuri Bainun Ipoh, Hospital Seri Manjung and Hospital Taiping).
This issue emcompasses various research articles written by CRC staff, a research scope write-up to emphasize on the research focus this coming year, programmes conducted in 2021 as well as upcoming events across the CRC Perak Network this year.
(e-ISSN Number: 2682-7867).
Preparedness for Covid 19 3rd wave ,.pptx
The document discusses preparedness for India's potential third wave of Covid-19, focusing on vaccination awareness and recommended precautions. It summarizes the history and characteristics of the first two waves, predicts younger children and adolescents may be more affected in the third wave. The document emphasizes the importance of vaccination, physical activity, nutrition, hygiene and continued safety measures like masks and distancing to reduce risks of severe illness.
2023JUL_Webinar_Ped QoC (1) (1).pptx by mitiku
The document summarizes a webinar on advancing pediatric quality of care held by the Child Health Task Force. It includes:
- Agenda items on sharing country efforts to improve pediatric quality from Kenya and Uganda, outcomes of recent discussions, and a roundtable discussion.
- Kenya has made progress developing pediatric quality standards and indicators, piloting a health facility assessment tool, and mapping indicators to their health information system. Challenges include resources for wide implementation and institutionalizing standards.
- Uganda has seen steady reductions in childhood mortality since 1989 through programs addressing leading causes of death. Future focus is strengthening health systems to support quality service delivery across all levels of care.
Leaving no one behind: Progress on Life Course Immunisation Roundtable – alon...
Leaving no one behind: Progress on Life Course Immunisation Roundtable – alongside the World Health Assembly
Date: Tuesday 23 May 2023
Time: 13.00 – 14.30 (CET), followed by refreshments
Location: Geneva Press Club, Geneva, Switzerland
Introduction and Malaysia’s Experience in Phase 1 Clinical Trials (old version)
Introduction and Malaysia’s Experience in Phase 1 Clinical Trials (old version)Institute for Clinical Research (ICR)
Webinar Series on Demystifying Phases in Clinical Trials & COVID-19 Updates organized by Institute for Clinical Research (ICR), NIH
Speaker: Dr. Alan Fong Yean Yip, Consultant Cardiologist & CRC head of Sarawak General Hospital and Mr. Chew Chun Keat, Technical Head of Centre for Clinical Trial, ICR
More information please visit: https://clinupcovid.mailerpage.com/resources/r0x8r9-webinar-series-on-demystifying-clStage is set for a strong link between1[1]
This document discusses the strong link between microbiology and epidemiology in Sri Lanka's immunization program (NIP). It summarizes key milestones in vaccine introduction and surveillance systems. It also discusses new partners like GAVI that have accelerated vaccine development and introduction plans. While new vaccines like Hib, JE, and pneumococcal may be introduced, sustainability, safety, and cost issues must be considered. Ongoing surveillance and research collaborations between epidemiologists and microbiologists will help inform decision making around introducing additional benefits of vaccines to the Sri Lankan public.
Vaccine security meeting - Overview of the who vaccine pre-qualification - O....
Vaccine security Meeting
Rome Italy FAO HQ
23-24 January 2020
Pillar I - Improve\1.3 Emerg Vacc\Vaccine Security Meeting\PPTs final
All about Covid-19 Vaccine Development
Disclaimer -
The Content belongs to WHO (World Health Organisation). Sharing here is just to spread awareness about Covid-19.
https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update37-vaccine-development.pdf?sfvrsn=2581e994_6
Arief Karfianto - Proposed Security Model for Protecting Patients Data in Ele...
This paper is a documentation of proposed security management for Electronic Health Records which includes security planning and policy, security program, risk management, and protection mechanism. Planning and policy are developed to provide a basic principle of security management at a hospital. The security program in this document includes Risk-Adaptable Access Control (RAdAC) and the implementation of security education, training and awareness (SETA). Regarding risk management, we perform risk identification, inventory of assets, information assets classification, and information assets value assessment, threat identification, and vulnerability assessment. For protection mechanism, we propose biometrics and signature as the authentication methods. The use of firewalls, intrusion detection system and encrypted data transmission is also suggested for securing data, application and network.
Certificate_Matilde Monjardino
This document is a certificate of attendance certifying that Matilde Pegado B. Monjardino successfully completed a Clinical Research Monitoring Course provided by Eurotrials, Centre for Clinical Research Training in Lisbon, Portugal between February 25th and April 29th, 2016, consisting of 48 hours of training. The course covered 9 modules on topics related to clinical trials including their history and regulations, study design, good clinical practice, the regulatory submission and approval process, implementation and monitoring of clinical trials, investigational medicinal products, pharmacovigilance, quality management, and clinical trial project management.
3.NISPID 2023 Pre-conference 2.pptx
Infectious Diseases Surveillance: Lessons Learned, Lessons to Learn .
PROF BECKIE NNENNA TAGBO (JP) MBBS, FCAI, FWACP (Paed), PhD, Vaccinology (Univ. Ghana & Cape Town), Advanced Vaccinology (Univ. Geneva), Epid Glob Health (Univ. Washington), Leadership & Mgt in Health (Univ. Washington), Glob Health Res (Univ. Washington)
✓ Director, Institute of Molecular Medicine and Infectious Diseases, College of Medicine, University of Nigeria.
✓ Professor of Paediatrics & Child Health, Department of Paediatrics, College of Medicine, University of Nigeria
✓ Chief Consultant Paediatrician, Department of Paediatrics/ Institute of Child Health, University of Nigeria teaching Hospital
• Chair of the WHO African Advisory Committee on Vaccine Safety (AACVS).
• Member, WHO (Global headquarters) Geneva, Global Advisory Committee on Vaccine Safety (GACVS) sub-committee on nOPV2 (novel oral polio vaccine type 2) Safety.
• Pioneered WHO AFRO / FED GOVT Rotavirus surveillance/ research for the first time in Nigeria in 2010 and thus headed the team that placed Nigeria on the World Health Organization Global map of rotavirus reporting countries of the world to WHO Global Headquarters at Geneva in 2010.
• Led the team that trained/established/mentored WHO AFRO Fed Govt/WHO AFRO rotavirus surveillance/research sites at UNTH Enugu(2010), UITH Ilorin(2013), ATBUTH Bauchi, ABUTH Zaria(both in Sept 2017).
• She has been involved in other new vaccines surveillance activities and has generated tremendous molecular/epidemiological data that has informed policy actions nationally and internationally.
• Site Coordinator for WHO AFRO intussusception and Paediatric Bacterial meningitis Sentinel Surveillance in Nigeria
• Principal investigator for several studies in infectious diseases
• Member, African Centre for Disease Control (CDC) Expert Committee for the development of the Pan-African Antimicrobial Standard Treatment Guidelines for Common Infections and Syndromes in Paediatric Patients.
• Fellow & Life member, West African College of Physicians (FWACP), in the Faculty of Paediatrics.
• Head, Paediatric Association of Nigeria Advisory Committee on Immunization from 2010 - 2022
• Member of many National working groups
• Member; National Ministerial Blueprint Committee on Routine Immunization.(As Immunization Field Expert)
• Member of 5 Working Groups of the GAIA/Brighton Collaboration
• Has vast experience in surveillance, research, policy meetings/consultation/special assignments, public health, vaccine clinical trial, immunization programme implementation /immunization training Consultant/Field Expert, advocacy, advisory committees,
• She is the Chief Editor of the 16-author Paediatric textbook titled “A Quick Glance at Paediatrics”
• Published many papers in both local and international high impact factor medical journals
• Journal Peer Reviewer for many journals
• Editorial Board Member for many journals
Awards
•Physician of the Year Award 2022 (Public sector)
Vaccine Safety Monitoring: Pharmacovigilance Strategies
Vaccine safety monitoring is a critical aspect of pharmacovigilance, particularly given the widespread use of vaccines to prevent infectious diseases. Robust surveillance systems are essential to detect and assess any potential adverse events following vaccination. Here are some key pharmacovigilance strategies employed for vaccine safety monitoring:
Passive Surveillance Systems:
Passive surveillance systems rely on healthcare providers, patients, and other stakeholders to voluntarily report adverse events following vaccination. These reports are collected in databases such as the Vaccine Adverse Event Reporting System (VAERS) in the United States or the Vaccine Adverse Event Surveillance System (VAESS) in other countries. While these systems are valuable for signal detection, they may suffer from underreporting and reporting bias.
Active Surveillance Systems:
Active surveillance involves proactively monitoring a defined population for adverse events following vaccination. This can be done through electronic health records (EHRs), claims databases, and other health data sources. The Vaccine Safety Datalink (VSD) in the United States is an example of an active surveillance system that uses large databases to continuously monitor vaccine safety.
Enhanced Surveillance and Cohort Studies:
Enhanced surveillance involves more intensive monitoring of a specific population or group of interest. Cohort studies are prospective studies that follow a group of vaccinated individuals over time to assess vaccine safety. These studies provide more detailed and controlled data compared to passive or active surveillance.
Comparative Effectiveness Research:
Comparative effectiveness research compares the safety of different vaccines or vaccination schedules. By analyzing large datasets, researchers can evaluate the relative risks and benefits of vaccines and identify any safety concerns.
Signal Detection and Analysis:
Data mining and statistical techniques are used to identify potential safety signals from adverse event reports. Signals are further investigated through in-depth analysis to determine if there is a causal relationship between the vaccine and the adverse event.
Causality Assessment:
Similar to general pharmacovigilance, causality assessment methods (such as the Naranjo Algorithm, WHO-UMC System, and Bayesian methods) are used to evaluate the likelihood of a causal relationship between a vaccine and an adverse event.
Risk Communication and Public Awareness:
Effective communication strategies are crucial to ensure that healthcare providers and the public are informed about vaccine safety. This involves providing clear and accurate information about potential risks and benefits.
Influenza molecular surveillance strategy
Presentation by Eeva Broberg of ECDC at the Joint WHO/Euro & ECDC Annual Influenza Surveillance Meeting, Vienna, Austria, 11–13 June 2014
VaccinateWConfidence-Immunization-Coordinators_508 (2).pptx
This document provides guidance for building confidence in COVID-19 vaccines among healthcare personnel and patients. It discusses the COVID-19 vaccines that are expected to receive emergency authorization, how they were tested and monitored for safety, and strategies for mitigating side effects like fever and soreness that may cause absenteeism. It also outlines elements of vaccine confidence like safety, effectiveness, and ease of access. Recommended strategies to increase confidence include engaging leaders to promote vaccines, addressing common concerns, and emphasizing the role of healthcare workers in ending the pandemic.
Weitzman ECHO COVID-19: Updates, Vaccines, and Lessons Learned So Far
This document provides an overview and update on COVID-19 from an infectious disease specialist's perspective for primary care providers. It discusses the current epidemiology in the US, reviews progress on serology tests, and emphasizes the importance of continuing prevention efforts. It also recognizes healthcare workers and provides resources for staying up-to-date on the pandemic.
E health for health it conference
This document provides an update on the Philippine eHealth Strategic Framework and Plan from May 2014. It summarizes the status of leadership and governance, standards and interoperability, workforce, infrastructure, and services and applications. Key actions include activating a Program Management Office for eHealth, prioritizing the Philippine Health Information Exchange, and ensuring transparency of eHealth governance.
IDPS programme update Sharon Webb
This document provides an update on the Infectious Diseases in Pregnancy Screening (IDPS) Programme in the UK. It discusses the aims of the programme, which include enabling early detection and treatment of infections in pregnancy to reduce mother-to-child transmission. It summarizes screening activity data which shows high uptake rates of over 99% for HIV, hepatitis B, and syphilis screening. It also discusses efforts to improve laboratory quality, establish screening standards and outcomes data, and provide education resources to professionals and the public. Specific updates are provided on actions relating to HIV, syphilis, hepatitis B, and developing seamless maternal and neonatal pathways between screening and immunization programs.
Patient Safety Middle East Conference Brochure
This document provides information on multiple medical conferences taking place from September 16-18, 2014 in Dubai, UAE. The conferences include the 10th Middle East Healthcare-Associated Infections Conference, the 4th Middle East Patient Safety Conference, the 4th Middle East Wound Care Conference, the 9th Middle East Decontamination and Sterilisation Conference, and the Smart Hospitals: The IT Solutions Conference. The document outlines the conference schedules, topics, speakers, and accreditation information. It encourages healthcare professionals to register for the conferences by the early bird deadline of August 14th.
Prescription to Your Doorstep for medicine delivery app
Medicine Delivery App Development offers a cutting-edge solution for pharmacies and healthcare providers looking to streamline the delivery of medications directly to patients' doorsteps. Our development services focus on creating user-friendly, secure, and efficient applications tailored to the specific needs of your business. With features like real-time tracking, secure payment gateways, and easy prescription management, we empower your service to improve patient care by ensuring timely and reliable medicine delivery. Our expert team uses the latest technology to build apps that are compatible with multiple devices and operating systems, enhancing accessibility for all users. Opt for Medicine Delivery App Development to elevate your pharmacy services, reduce wait times, and provide a seamless, convenient experience for your customers.
SMi Group's 4th annual Immunogenicity 2017 conference
This document provides information about an upcoming conference on immunogenicity taking place from June 12-13, 2017 in London. The conference will focus on standardizing immunogenicity methods, regulatory considerations, novel approaches to reducing immunogenicity, developments for biologic drugs and immunogenicity predictions, and emerging solutions. It lists the program agenda with topics such as predictive tools for immunogenicity, reporting clinically relevant data, cut point setting, EU guidance, ADA-dependent reactions, personalizing therapy, tolerogenic nanoparticles, and a panel on human versus humanized antibodies. Speakers are from organizations like Regeneron, NIBSC, EpiVax, Novartis, Abbvie, Merck, Roche, and Immun
TGA Presentation: Pharmacovigilance inspections
An update on the Pharmacovigilance Inspection Program, practical tips for inspections and developing a Corrective And Preventive Plan
The Philippines eHealth Strategic Framework and Plan (Updates as of May 23, 2...
This document summarizes the status of the Philippine eHealth Strategic Framework and Plan as of May 2014. Key updates include expanding stakeholder representation on the National eHealth Steering Committee, completing COBIT training to improve IT governance, and prioritizing the implementation of the Philippine Health Information Exchange to enable interoperability between health systems. Overall progress is monitored using a traffic light system and recommended next steps are to activate the eHealth Program Management Office and further engage stakeholders.
Vaccine Development.pptx
This document provides an overview of COVID-19 vaccine development. It discusses that vaccines work by training the immune system to recognize pathogens. There are many COVID-19 vaccines in development because different types may be needed for different groups, and it is unknown which will be effective and safe. The document outlines various vaccine platforms including viral vectors, protein-based, and nucleic acid vaccines. It notes that 10 candidates are in Phase III trials. Accelerated development is occurring with parallel steps rather than sequentially to more quickly produce a safe and effective vaccine.
PEA .pptx
1. Pulseless electrical activity (PEA) is characterized by organized cardiac electrical activity but an absence of peripheral pulses and blood pressure due to a lack of meaningful cardiac contractions.
2. PEA occurs when cardiovascular, respiratory, or metabolic derangements weaken cardiac contraction to the point where the heart cannot generate sufficient force in response to electrical signals.
3. The most common cause of PEA is hypoxia from respiratory failure, which creates a vicious cycle of worsening acidosis and contractility that leads to degradation of the cardiac rhythm.
More Related Content
Similar to PPV UNiSZ Experience.pptx
Leaving no one behind: Progress on Life Course Immunisation Roundtable – alon...
Leaving no one behind: Progress on Life Course Immunisation Roundtable – alongside the World Health Assembly
Date: Tuesday 23 May 2023
Time: 13.00 – 14.30 (CET), followed by refreshments
Location: Geneva Press Club, Geneva, Switzerland
Introduction and Malaysia’s Experience in Phase 1 Clinical Trials (old version)
Introduction and Malaysia’s Experience in Phase 1 Clinical Trials (old version)Institute for Clinical Research (ICR)
Webinar Series on Demystifying Phases in Clinical Trials & COVID-19 Updates organized by Institute for Clinical Research (ICR), NIH
Speaker: Dr. Alan Fong Yean Yip, Consultant Cardiologist & CRC head of Sarawak General Hospital and Mr. Chew Chun Keat, Technical Head of Centre for Clinical Trial, ICR
More information please visit: https://clinupcovid.mailerpage.com/resources/r0x8r9-webinar-series-on-demystifying-clStage is set for a strong link between1[1]
This document discusses the strong link between microbiology and epidemiology in Sri Lanka's immunization program (NIP). It summarizes key milestones in vaccine introduction and surveillance systems. It also discusses new partners like GAVI that have accelerated vaccine development and introduction plans. While new vaccines like Hib, JE, and pneumococcal may be introduced, sustainability, safety, and cost issues must be considered. Ongoing surveillance and research collaborations between epidemiologists and microbiologists will help inform decision making around introducing additional benefits of vaccines to the Sri Lankan public.
Vaccine security meeting - Overview of the who vaccine pre-qualification - O....
Vaccine security Meeting
Rome Italy FAO HQ
23-24 January 2020
Pillar I - Improve\1.3 Emerg Vacc\Vaccine Security Meeting\PPTs final
All about Covid-19 Vaccine Development
Disclaimer -
The Content belongs to WHO (World Health Organisation). Sharing here is just to spread awareness about Covid-19.
https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update37-vaccine-development.pdf?sfvrsn=2581e994_6
Arief Karfianto - Proposed Security Model for Protecting Patients Data in Ele...
This paper is a documentation of proposed security management for Electronic Health Records which includes security planning and policy, security program, risk management, and protection mechanism. Planning and policy are developed to provide a basic principle of security management at a hospital. The security program in this document includes Risk-Adaptable Access Control (RAdAC) and the implementation of security education, training and awareness (SETA). Regarding risk management, we perform risk identification, inventory of assets, information assets classification, and information assets value assessment, threat identification, and vulnerability assessment. For protection mechanism, we propose biometrics and signature as the authentication methods. The use of firewalls, intrusion detection system and encrypted data transmission is also suggested for securing data, application and network.
Certificate_Matilde Monjardino
This document is a certificate of attendance certifying that Matilde Pegado B. Monjardino successfully completed a Clinical Research Monitoring Course provided by Eurotrials, Centre for Clinical Research Training in Lisbon, Portugal between February 25th and April 29th, 2016, consisting of 48 hours of training. The course covered 9 modules on topics related to clinical trials including their history and regulations, study design, good clinical practice, the regulatory submission and approval process, implementation and monitoring of clinical trials, investigational medicinal products, pharmacovigilance, quality management, and clinical trial project management.
3.NISPID 2023 Pre-conference 2.pptx
Infectious Diseases Surveillance: Lessons Learned, Lessons to Learn .
PROF BECKIE NNENNA TAGBO (JP) MBBS, FCAI, FWACP (Paed), PhD, Vaccinology (Univ. Ghana & Cape Town), Advanced Vaccinology (Univ. Geneva), Epid Glob Health (Univ. Washington), Leadership & Mgt in Health (Univ. Washington), Glob Health Res (Univ. Washington)
✓ Director, Institute of Molecular Medicine and Infectious Diseases, College of Medicine, University of Nigeria.
✓ Professor of Paediatrics & Child Health, Department of Paediatrics, College of Medicine, University of Nigeria
✓ Chief Consultant Paediatrician, Department of Paediatrics/ Institute of Child Health, University of Nigeria teaching Hospital
• Chair of the WHO African Advisory Committee on Vaccine Safety (AACVS).
• Member, WHO (Global headquarters) Geneva, Global Advisory Committee on Vaccine Safety (GACVS) sub-committee on nOPV2 (novel oral polio vaccine type 2) Safety.
• Pioneered WHO AFRO / FED GOVT Rotavirus surveillance/ research for the first time in Nigeria in 2010 and thus headed the team that placed Nigeria on the World Health Organization Global map of rotavirus reporting countries of the world to WHO Global Headquarters at Geneva in 2010.
• Led the team that trained/established/mentored WHO AFRO Fed Govt/WHO AFRO rotavirus surveillance/research sites at UNTH Enugu(2010), UITH Ilorin(2013), ATBUTH Bauchi, ABUTH Zaria(both in Sept 2017).
• She has been involved in other new vaccines surveillance activities and has generated tremendous molecular/epidemiological data that has informed policy actions nationally and internationally.
• Site Coordinator for WHO AFRO intussusception and Paediatric Bacterial meningitis Sentinel Surveillance in Nigeria
• Principal investigator for several studies in infectious diseases
• Member, African Centre for Disease Control (CDC) Expert Committee for the development of the Pan-African Antimicrobial Standard Treatment Guidelines for Common Infections and Syndromes in Paediatric Patients.
• Fellow & Life member, West African College of Physicians (FWACP), in the Faculty of Paediatrics.
• Head, Paediatric Association of Nigeria Advisory Committee on Immunization from 2010 - 2022
• Member of many National working groups
• Member; National Ministerial Blueprint Committee on Routine Immunization.(As Immunization Field Expert)
• Member of 5 Working Groups of the GAIA/Brighton Collaboration
• Has vast experience in surveillance, research, policy meetings/consultation/special assignments, public health, vaccine clinical trial, immunization programme implementation /immunization training Consultant/Field Expert, advocacy, advisory committees,
• She is the Chief Editor of the 16-author Paediatric textbook titled “A Quick Glance at Paediatrics”
• Published many papers in both local and international high impact factor medical journals
• Journal Peer Reviewer for many journals
• Editorial Board Member for many journals
Awards
•Physician of the Year Award 2022 (Public sector)
Vaccine Safety Monitoring: Pharmacovigilance Strategies
Vaccine safety monitoring is a critical aspect of pharmacovigilance, particularly given the widespread use of vaccines to prevent infectious diseases. Robust surveillance systems are essential to detect and assess any potential adverse events following vaccination. Here are some key pharmacovigilance strategies employed for vaccine safety monitoring:
Passive Surveillance Systems:
Passive surveillance systems rely on healthcare providers, patients, and other stakeholders to voluntarily report adverse events following vaccination. These reports are collected in databases such as the Vaccine Adverse Event Reporting System (VAERS) in the United States or the Vaccine Adverse Event Surveillance System (VAESS) in other countries. While these systems are valuable for signal detection, they may suffer from underreporting and reporting bias.
Active Surveillance Systems:
Active surveillance involves proactively monitoring a defined population for adverse events following vaccination. This can be done through electronic health records (EHRs), claims databases, and other health data sources. The Vaccine Safety Datalink (VSD) in the United States is an example of an active surveillance system that uses large databases to continuously monitor vaccine safety.
Enhanced Surveillance and Cohort Studies:
Enhanced surveillance involves more intensive monitoring of a specific population or group of interest. Cohort studies are prospective studies that follow a group of vaccinated individuals over time to assess vaccine safety. These studies provide more detailed and controlled data compared to passive or active surveillance.
Comparative Effectiveness Research:
Comparative effectiveness research compares the safety of different vaccines or vaccination schedules. By analyzing large datasets, researchers can evaluate the relative risks and benefits of vaccines and identify any safety concerns.
Signal Detection and Analysis:
Data mining and statistical techniques are used to identify potential safety signals from adverse event reports. Signals are further investigated through in-depth analysis to determine if there is a causal relationship between the vaccine and the adverse event.
Causality Assessment:
Similar to general pharmacovigilance, causality assessment methods (such as the Naranjo Algorithm, WHO-UMC System, and Bayesian methods) are used to evaluate the likelihood of a causal relationship between a vaccine and an adverse event.
Risk Communication and Public Awareness:
Effective communication strategies are crucial to ensure that healthcare providers and the public are informed about vaccine safety. This involves providing clear and accurate information about potential risks and benefits.
Influenza molecular surveillance strategy
Presentation by Eeva Broberg of ECDC at the Joint WHO/Euro & ECDC Annual Influenza Surveillance Meeting, Vienna, Austria, 11–13 June 2014
VaccinateWConfidence-Immunization-Coordinators_508 (2).pptx
This document provides guidance for building confidence in COVID-19 vaccines among healthcare personnel and patients. It discusses the COVID-19 vaccines that are expected to receive emergency authorization, how they were tested and monitored for safety, and strategies for mitigating side effects like fever and soreness that may cause absenteeism. It also outlines elements of vaccine confidence like safety, effectiveness, and ease of access. Recommended strategies to increase confidence include engaging leaders to promote vaccines, addressing common concerns, and emphasizing the role of healthcare workers in ending the pandemic.
Weitzman ECHO COVID-19: Updates, Vaccines, and Lessons Learned So Far
This document provides an overview and update on COVID-19 from an infectious disease specialist's perspective for primary care providers. It discusses the current epidemiology in the US, reviews progress on serology tests, and emphasizes the importance of continuing prevention efforts. It also recognizes healthcare workers and provides resources for staying up-to-date on the pandemic.
E health for health it conference
This document provides an update on the Philippine eHealth Strategic Framework and Plan from May 2014. It summarizes the status of leadership and governance, standards and interoperability, workforce, infrastructure, and services and applications. Key actions include activating a Program Management Office for eHealth, prioritizing the Philippine Health Information Exchange, and ensuring transparency of eHealth governance.
IDPS programme update Sharon Webb
This document provides an update on the Infectious Diseases in Pregnancy Screening (IDPS) Programme in the UK. It discusses the aims of the programme, which include enabling early detection and treatment of infections in pregnancy to reduce mother-to-child transmission. It summarizes screening activity data which shows high uptake rates of over 99% for HIV, hepatitis B, and syphilis screening. It also discusses efforts to improve laboratory quality, establish screening standards and outcomes data, and provide education resources to professionals and the public. Specific updates are provided on actions relating to HIV, syphilis, hepatitis B, and developing seamless maternal and neonatal pathways between screening and immunization programs.
Patient Safety Middle East Conference Brochure
This document provides information on multiple medical conferences taking place from September 16-18, 2014 in Dubai, UAE. The conferences include the 10th Middle East Healthcare-Associated Infections Conference, the 4th Middle East Patient Safety Conference, the 4th Middle East Wound Care Conference, the 9th Middle East Decontamination and Sterilisation Conference, and the Smart Hospitals: The IT Solutions Conference. The document outlines the conference schedules, topics, speakers, and accreditation information. It encourages healthcare professionals to register for the conferences by the early bird deadline of August 14th.
Prescription to Your Doorstep for medicine delivery app
Medicine Delivery App Development offers a cutting-edge solution for pharmacies and healthcare providers looking to streamline the delivery of medications directly to patients' doorsteps. Our development services focus on creating user-friendly, secure, and efficient applications tailored to the specific needs of your business. With features like real-time tracking, secure payment gateways, and easy prescription management, we empower your service to improve patient care by ensuring timely and reliable medicine delivery. Our expert team uses the latest technology to build apps that are compatible with multiple devices and operating systems, enhancing accessibility for all users. Opt for Medicine Delivery App Development to elevate your pharmacy services, reduce wait times, and provide a seamless, convenient experience for your customers.
SMi Group's 4th annual Immunogenicity 2017 conference
This document provides information about an upcoming conference on immunogenicity taking place from June 12-13, 2017 in London. The conference will focus on standardizing immunogenicity methods, regulatory considerations, novel approaches to reducing immunogenicity, developments for biologic drugs and immunogenicity predictions, and emerging solutions. It lists the program agenda with topics such as predictive tools for immunogenicity, reporting clinically relevant data, cut point setting, EU guidance, ADA-dependent reactions, personalizing therapy, tolerogenic nanoparticles, and a panel on human versus humanized antibodies. Speakers are from organizations like Regeneron, NIBSC, EpiVax, Novartis, Abbvie, Merck, Roche, and Immun
TGA Presentation: Pharmacovigilance inspections
An update on the Pharmacovigilance Inspection Program, practical tips for inspections and developing a Corrective And Preventive Plan
The Philippines eHealth Strategic Framework and Plan (Updates as of May 23, 2...
This document summarizes the status of the Philippine eHealth Strategic Framework and Plan as of May 2014. Key updates include expanding stakeholder representation on the National eHealth Steering Committee, completing COBIT training to improve IT governance, and prioritizing the implementation of the Philippine Health Information Exchange to enable interoperability between health systems. Overall progress is monitored using a traffic light system and recommended next steps are to activate the eHealth Program Management Office and further engage stakeholders.
Vaccine Development.pptx
This document provides an overview of COVID-19 vaccine development. It discusses that vaccines work by training the immune system to recognize pathogens. There are many COVID-19 vaccines in development because different types may be needed for different groups, and it is unknown which will be effective and safe. The document outlines various vaccine platforms including viral vectors, protein-based, and nucleic acid vaccines. It notes that 10 candidates are in Phase III trials. Accelerated development is occurring with parallel steps rather than sequentially to more quickly produce a safe and effective vaccine.
Similar to PPV UNiSZ Experience.pptx (20)
Leaving no one behind: Progress on Life Course Immunisation Roundtable – alon...
Leaving no one behind: Progress on Life Course Immunisation Roundtable – alon...
Introduction and Malaysia’s Experience in Phase 1 Clinical Trials (old version)
Introduction and Malaysia’s Experience in Phase 1 Clinical Trials (old version)
Vaccine security meeting - Overview of the who vaccine pre-qualification - O....
Vaccine security meeting - Overview of the who vaccine pre-qualification - O....
Arief Karfianto - Proposed Security Model for Protecting Patients Data in Ele...
Arief Karfianto - Proposed Security Model for Protecting Patients Data in Ele...
Vaccine Safety Monitoring: Pharmacovigilance Strategies
Vaccine Safety Monitoring: Pharmacovigilance Strategies
VaccinateWConfidence-Immunization-Coordinators_508 (2).pptx
VaccinateWConfidence-Immunization-Coordinators_508 (2).pptx
Weitzman ECHO COVID-19: Updates, Vaccines, and Lessons Learned So Far
Weitzman ECHO COVID-19: Updates, Vaccines, and Lessons Learned So Far
Prescription to Your Doorstep for medicine delivery app
Prescription to Your Doorstep for medicine delivery app
SMi Group's 4th annual Immunogenicity 2017 conference
SMi Group's 4th annual Immunogenicity 2017 conference
The Philippines eHealth Strategic Framework and Plan (Updates as of May 23, 2...
The Philippines eHealth Strategic Framework and Plan (Updates as of May 23, 2...
More from drnikahmad
PEA .pptx
1. Pulseless electrical activity (PEA) is characterized by organized cardiac electrical activity but an absence of peripheral pulses and blood pressure due to a lack of meaningful cardiac contractions.
2. PEA occurs when cardiovascular, respiratory, or metabolic derangements weaken cardiac contraction to the point where the heart cannot generate sufficient force in response to electrical signals.
3. The most common cause of PEA is hypoxia from respiratory failure, which creates a vicious cycle of worsening acidosis and contractility that leads to degradation of the cardiac rhythm.
SWOT may 2021.pdf
The document provides information on how to conduct a SWOT analysis, including definitions and examples. It discusses analyzing the internal and external context of an organization using the PRIMO-F and PESTLE frameworks. It then provides two examples of SWOT analyses conducted on universities:
1) The University of Illinois Springfield is analyzed, noting its strengths like its U of I name and location in the state capital, and weaknesses like underfunding and lack of diversity.
2) A SWOT is performed on Universiti Malaysia Kelantan, identifying strengths such as affordable tuition but also weaknesses such as inadequate facilities and resources.
The document emphasizes that tools like SWOT, PRIMO-F, and PESTLE are
Values in Medicine Professionalism.ppt
This document discusses the values of medical professionalism. It defines professional competence as using communication, knowledge and skills for patient benefit. Key attributes of professionalism include responsibility, competence, respect, social responsibility, honesty, health, functioning under stress, appearance, tolerance, dependability, and research ethics. The document outlines expectations for students to prioritize patient needs, maintain learning and skills, respect others, conduct themselves with integrity, and assess their own health.
The beautiful mind.pdf
This case report describes the successful removal of nine constricting rings from the fingers of a poorly cared for schizophrenia patient in the emergency department. The patient had a history of recurrent schizophrenia relapses and non-adherence to treatment. Attempts to remove the rings previously had failed and led to infection and gangrene requiring amputation. In this instance, the rings were removed using procedural sedation with midazolam and fentanyl along with a wrist block. Support from family is important to prevent future recurrence and negligence in caring for schizophrenia patients. Early intervention and treatment is crucial to avoid permanent injury.
Upper airway assessment east iv
This document provides an outline for a presentation on upper airway assessment. It begins with an introduction emphasizing the importance of securing the airway. It then reviews adult and pediatric airway anatomy and differences. The presentation covers approaching upper airway assessment, including examining speech, appearance, listening, and considering risk factors. It describes predictors of a difficult airway and grades of laryngoscopic views. The document also summarizes factors that can make bag-valve-mask ventilation, placement of extraglottic devices, and cricothyrotomy difficult. Throughout, it stresses preparing for potential airway challenges and knowing when to request help.
Emergency us physics and instrumentation
This document provides an introduction to ultrasound physics and instrumentation for beginners. It discusses how ultrasound works, including how sound waves are produced and reflected, ultrasound modes like B-mode and Doppler, common artifacts, probe types, and basic terminology. The key points are that ultrasound uses piezoelectric crystals to produce high-frequency sound pulses that penetrate the body and reflect off boundaries between tissues, and the reflected echoes are used to form images on the screen based on pulse-echo timing and intensities.
Role and responsibility of First Responders In MOH
Dokumen tersebut membahas tentang tugas, tanggung jawab, dan etika first responder dalam memberikan perawatan pertolongan pertama. Ia menjelaskan bahwa first responder adalah orang pertama yang tiba di tempat kejadian dan terlatih untuk memberikan perawatan awal. Dokumen tersebut juga membahas tentang nilai-nilai integritas seperti kejujuran, tanggung jawab, dan komitmen dalam pelaksanaan tugas first responder.
More from drnikahmad (13)
1ST ANNOUNCEMENT EMAS - SUCCES - EMS SEA TRIPARTITE 2022 (1).pdf
1ST ANNOUNCEMENT EMAS - SUCCES - EMS SEA TRIPARTITE 2022 (1).pdf
Role and responsibility of First Responders In MOH
Role and responsibility of First Responders In MOH
Recently uploaded
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS). Parc Taulí. Sabadell
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
It includes regulation of combination products and medical devices. FDA and industry liaisons.
A Classical Text Review on Basavarajeeyam
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Ketone bodies and metabolism-biochemistry
This slide consists of all the topics of ketone . This can be used for exam purpose for writing about Diabetic keto acidosis etc . Thank you
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...rightmanforbloodline
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.share - Lions, tigers, AI and health misinformation, oh my!.pptx
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Best Ayurvedic medicine for Gas and Indigestion
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Recently uploaded (20)
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
PPV UNiSZ Experience.pptx
- 1. 1 INTERNATIONAL WEBINARS ON INFECTIOUS DISEASES: COVID-19 “PPV IPT (Integrasi) @ UniSZA”: Our Experience DATE: 3rd August 2021 TIME: 1400-1600 PM PLATFORM : WEBEX Centre For Infectious Diseases & Biotechnology (CeRIDB)
- 2. Sharing list 1. Malaysian Vaccination Programme at glance 2. UniSZA Vaccination Centre: What we do? 3. Issues & Challenges 4. Lesson identified & Lesson Learnt 5. Summary
- 3. Welcome
- 4. 16th Feb 2021 4 Malaysian Vaccination Programme at glance
- 5. First in Malaysia – Received Pfizer- BioNTech, Wednesday 24th February 2021 5
- 7. 7
- 8. Vaccination Process 8 1. Registration & Covid-19 screening 2. Pre vaccine assessment 3. Consent 4. Vaccination 5. Post vaccine observation UniSZA Vaccination Centre: What we do?
- 9. 9 UniSZA Vaccination Centre: What we do?
- 10. 1. Administration • Covid-19 SOP’s adherence • Client data management 2. Quality assurance • Audit • Vaccine management/Cold chain 3. Vaccinator • Skill training • Wastage 4. Adverse event following immunisation (AEFI) 5. Others Issues & Challenges
- 11. Issues & Challenges - Administration SOP’s Adherence
- 12. Issues & Challenges - Administration Client data management Turn at our PPV – Client registered at other place Missing in action after vaccination
- 13. Quality Assurance – Audit visit • Ministry of Health Malaysia • State Health Department of Terengganu • Pharmaceutical Department • National Security Counsel • Covid-19 Immunization Task Force • District Office
- 14. Quality assurance – Vaccine management/Cold chain Inadequate vaccine volume Electrical supply - temperature
- 16. Issues & Challenges - Adverse event following immunization (AEFI) • Total 8 cases refer require extended observation at hospitals • 20 cases manage at facility
- 17. Issues & Challenges - Others Cleanliness Close contact
- 18. Need to establish a good relation with the media/NGO’s
- 20. 1. Capability 2. Capacity 3. Coordination 4. Command 5. Control 6. Communication 7. Cooperation 8. Cleanliness Lesson Identified, Lesson Learnt
- 21. Summary 1. Capability ready – vaccine supply according to locality 2. Malaysia – towards earlier herd immunity. 3. PPV IPT (Integrasi) @ UniSZA 1.5K – 2.5K per day …. Total > 30K 4. AEFI < 1% and majority manageable at facility 5. Support from stake holders is mandatory
- 22. Thank you